Top life science executives join Broken String Biosciences board
Broken String is enabling development of the next generation of more precise, safe, and effective cell and gene therapies.
Bringing extensive commercial and leadership expertise, Reid and Crutchfield are destined to play a pivotal role in providing strategic oversight as Broken String prepares for its next phase of commercial growth.
Working closely with CEO Felix Dobbs, they will help advance the company's INDUCE-seq® product offering to address the significant unmet needs of its global customer base within the expanding cell and gene therapy market.
Reid is a seasoned biotech entrepreneur with a track record of leadership and company-building success within the sector, previously CEO at Decibel Therapeutics (acquired by Regeneron Pharmaceuticals) and Warp Drive Bio (merged with Revolution Medicines).
He served as entrepreneur in residence at Third Rock Ventures, focused on novel drug discovery and development opportunities. Prior to this, he held C-level executive positions at Alnylam Pharmaceuticals, Ensemble Discovery and Millennium Pharmaceuticals.
Crutchfield brings nearly 40 years’ experience in the development and commercialisation of life science tools. Most recently, he served as Chief Commercial Officer of 10x Genomics, building the global sales and support organisation that today drives over $600 million in business, and working closely with the CEO to support the company through its IPO in 2019.
Previously, he has held several leadership positions, including as Senior Vice President, Life Sciences at QIAGEN, Vice President and General Manager, EMEA at Illumina, and President of the Life Science Group at Bio-Rad Laboratories.
Broken String CEO Felix Dobbs said: “Laurence and Brad bring distinguished careers and a strong history of driving impact and growth within our industry. As we push forward with our ambitious growth strategy and work to achieve our commercial goals, their expertise will be instrumental in shaping our strategic direction.”